Clinical Research Directory
Browse clinical research sites, groups, and studies.
Smoking Harm Reduction Using E-cigarettes and Cytisine
Sponsor: Centre for Addiction and Mental Health
Summary
Smoking remains the leading cause of preventable death globally, with high prevalence in disadvantaged populations despite access to free nicotine replacement therapy (NRT) and counseling through Ontario's STOP Program. This study aims to evaluate the acceptability, feasibility, and comparative effectiveness of e-cigarettes and cytisine as harm-reduction tools for individuals who continue to smoke despite standard treatments. Over four years, 6,000 STOP participants who smoke ≥5 cigarettes daily at six months post-treatment will be randomized to receive either an e-cigarette starter kit or a 28-day cytisine supply. Data will be collected via REDCap and include biomarkers (NNAL, PAH), self-reported smoking behavior, nicotine dependence, and quality of life. Statistical analyses will assess changes and compare outcomes between groups. Results will inform public health strategies and enhance equitable cessation support for underserved populations.
Official title: Exploring Alternative Approaches to Harm Reduction and Cessation for Treatment-Resistant Tobacco Dependence
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6000
Start Date
2026-05-01
Completion Date
2028-03
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
E-cigarette e-liquid
E-cigarette used as a smoking cessation intervention
Cytisine
Cytisine used as a smoking cessation intervention